DNMT1 and Burkitt lymphoma: Alteration of DNA methylation has also been proven to be effective in modulating TRAIL response of hepatoma, Burkitt’s lymphoma, SCLC cells as exemplified by 5-aza-2′-deoxycytidine treatment15,25, combination treatment of decitabine and Valproic acid26, treatment with DNMT1 inhibitor Iso-327 and by DNMT1 and DNMT3b silencing28.